A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older | MicrobiomeTrials
A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
CompletedPHASE3INTERVENTIONAL
Trial Details
Start: 2023-10-24Est. Completion: 2024-02-19
Enrollment target: 959 participants
Locations
Medical Affiliated Research Center Inc. (MARC), Huntsville, Alabama, United States
Alliance for Multispeciality Research, Mobile, Alabama, United States
Artemis Institute for Clinical Research, San Diego, California, United States
Diablo Clinical Research, Inc., Walnut Creek, California, United States
Optimal Research, Melbourne, Florida, United States
Pharmax Research Clinic Inc, Miami, Florida, United States
Suncoast Research Associates, LLC, Miami, Florida, United States
Atlanta Center for Medical Research, Atlanta, Georgia, United States
Velocity Clinical Research, Savannah, Georgia, United States
Synexus Clinical Research US Inc, Chicago, Illinois, United States
Optimal Research, Peoria, Illinois, United States
Synexus Radiant Research, Inc, Evansville, Indiana, United States
Heartland Research Associates, LLC, Newton, Kansas, United States
Heartland Research Associates, an AMR Company, Wichita, Kansas, United States
Alliance for Multispeciality Research, Lexington, Kentucky, United States
Other microbiome trials you might be interested in